Cooper Financial Group Sells 875 Shares of McKesson Corporation $MCK

Posted by George Bondi on Aug 8th, 2026

Cooper Financial Group trimmed its holdings in McKesson Corporation (NYSE:MCK – Free Report) by 34.0% in the second quarter, Holdings Channel reports. The institutional investor owned 1,702 shares of the company’s stock after selling 875 shares during the quarter. Cooper Financial Group’s holdings in McKesson were worth $1,286,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of MCK. Czech National Bank grew its position in shares of McKesson by 2.6% in the second quarter. Czech National Bank now owns 34,215 shares of the company’s stock valued at $25,853,000 after purchasing an additional 856 shares in the last quarter. PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in McKesson by 8.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 30,850 shares of the company’s stock worth $23,310,000 after purchasing an additional 2,525 shares during the period. Apella Capital LLC grew its holdings in McKesson by 3.4% during the 2nd quarter. Apella Capital LLC now owns 612 shares of the company’s stock valued at $494,000 after buying an additional 20 shares in the last quarter. Mechanics Bank Trust Department grew its holdings in McKesson by 11.5% during the 2nd quarter. Mechanics Bank Trust Department now owns 5,043 shares of the company’s stock valued at $3,810,000 after buying an additional 519 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC increased its position in shares of McKesson by 2.6% during the second quarter. Dynamic Advisor Solutions LLC now owns 1,286 shares of the company’s stock valued at $972,000 after buying an additional 32 shares during the period. Institutional investors own 85.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MCK shares. William Blair assumed coverage on shares of McKesson in a research report on Tuesday, April 28th. They issued an “outperform” rating for the company. Wells Fargo & Company lowered their target price on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. JPMorgan Chase & Co. cut their price target on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Citigroup boosted their price target on shares of McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $875.00 price target on shares of McKesson in a report on Friday, May 8th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $968.93.

Check Out Our Latest Analysis on McKesson

McKesson Price Performance

Shares of McKesson stock opened at $871.72 on Friday. The stock has a market capitalization of $101.63 billion, a P/E ratio of 23.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.30. The business’s 50 day simple moving average is $800.68 and its two-hundred day simple moving average is $840.98. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, topping the consensus estimate of $9.56 by $0.37. The firm had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company posted $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Sell-side analysts expect that McKesson Corporation will post 44.38 earnings per share for the current fiscal year.

McKesson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, September 1st. This is a positive change from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 8.53%.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

Positive Sentiment: Quarterly results exceeded expectations. McKesson reported adjusted earnings of $9.93 per share, ahead of the $9.44-$9.56 analyst consensus range, while revenue rose 7.7% year over year to $105.38 billion, topping estimates. EPS also increased from $8.26 in the prior-year quarter. McKesson Q1 Earnings and Revenues Top Estimates
Positive Sentiment: Specialty pharmaceutical growth drove profitability. Pharma profit rose 19%, supported by specialty medicine demand and oncology growth. Management raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly in line with or above current analyst expectations. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
Positive Sentiment: Capital returns are becoming more attractive. McKesson plans approximately $5 billion in share repurchases and raised its dividend by 15%, potentially supporting per-share earnings and investor sentiment. McKesson Outlines Fiscal 2027 EPS and Share Repurchases
Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned spinoff and potential IPO. The move could unlock value, although it also introduces execution and separation risks. McKesson Debuts Wellverse Name
Neutral Sentiment: Recent Zacks commentary characterizes MCK as a growth stock, citing earnings growth, specialty-drug exposure and improving fundamentals. However, these articles are analytical opinions rather than new company announcements. McKesson Is an Incredible Growth Stock

Insider Buying and Selling

In related news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the sale, the chief accounting officer owned 632 shares in the company, valued at $482,848. This represents a 17.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 699 shares of McKesson stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total value of $513,953.73. Following the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,667,592.36. The trade was a 23.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 28,748 shares of company stock valued at $22,262,035. 0.06% of the stock is owned by company insiders.

McKesson Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.